ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1770

Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation

Chrong-Reen Wang1, Shih-Yao Chen 1, Yu-Chi Chou 2, Chao-Liang Wu 3, Yu-Ting Lo 1 and Ai-Li Shiau 4, 1National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), 2Genomics Research Center, Academia Sinica, Taipei, Taiwan (Republic of China), 3National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China), 4National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China)

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: animal models and tumor necrosis factor (TNF), pathogenesis, rheumatoid arthritis, Rheumatoid arthritis (RA), WNT Signaling

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 4M093: RA – Animal Models (1770–1775)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Long non-coding RNAs (lncRNAs) participate in the rheumatoid arthritis (RA) pathogenesis. The aim of this study was to examine the lncRNA H19 and HOTAIR expression in RA patients, and whether delivery of CRISPR interference (CRISPRi) with catalytically dead Cas9 (dCas9) targeting H19 can ameliorate the experimental rheumatoid joint.

Methods: Synovial tissue (ST) and venous blood samples were obtained from RA and osteoarthritis (OA) patients. Synovial fibroblasts (SFs) were purified from ST, and normal SFs were acquired commercially. To generate CRISPRi-H19 and CRISPRi-HOTAIR, guide RNA spacer sequences targeting H19 or HOTAIR were cloned into the CRISPRi vector containing the dCas9/Krüppel-associated box repressor domain with an efficient transcription repression ability. SFs and 293T cells were transduced with CRISPRi-H19 and CRISPRi-HOTAIR, respectively, to create stable transfectants. Therapeutic effects of intra-articular CRISPRi-H19 injection were assessed in a rat model of collagen-induced arthritis. LncRNAs expression were examined by quantitative real-time PCR. Cell invasion was assayed by Transwells with membrane coated with Matrigel.

Results: Increased synovial and peripheral H19 levels were found in RA patients with decreased H19 expression in venous mononuclear cells (MNCs) after a TNF  blockade (adalimumab) therapy as compared with OA counterparts. There were higher HOTAIR levels in MNCs from RA patients, but no differences after the anti-TNF therapy. H19 levels in SFs were enhanced by the TNF stimulation. Reduced H19, pGSK-3β (Wnt signaling), EZH2 and Snail expression, cell invasion and IL-6 production with increased Nkd1 (Wnt inhibitor) expression were identified in H19-silenced SF transfectants. Decreased Tri-Methyl-H3K27 expression were found in HOTAIR-silenced 293T transfectants. Lower arthritis indexes and histological scores with less erosion on cartilage/bone were demonstrated in the CRISPRi-H19-injected joints with enhanced NKd1 and decreased H19, pGSK-3β, EZH2, Snail and IL-6 expression, suggesting silencing H19 to ameliorate experimental rheumatoid joint through inactivating the Wnt signaling.

Conclusion: Our results demonstrate that intra-articular delivery of CRISPRi targeting lncRNA can alleviate the experimental rheumatoid joint. Such findings might contribute to the development of lncRNAs-related therapeutics in RA patients.


Disclosure: C. Wang, None; S. Chen, None; Y. Chou, None; C. Wu, None; Y. Lo, None; A. Shiau, None.

To cite this abstract in AMA style:

Wang C, Chen S, Chou Y, Wu C, Lo Y, Shiau A. Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/experimental-rheumatoid-joint-ameliorated-by-crispr-interference-targeting-long-non-coding-rna-h19-through-wnt-signaling-inactivation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/experimental-rheumatoid-joint-ameliorated-by-crispr-interference-targeting-long-non-coding-rna-h19-through-wnt-signaling-inactivation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology